This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Progenics Pharmaceuticals, Inc.
Drug Names(s): PSMA Subunit Vaccine
Description: CYT-500 is a therapeutic recombinant protein vaccine linked to Lutetium 177 (Lu-177), a particle emitting therapeutic radionuclide, and is designed to stimulate a patient’s immune system to recognize and destroy prostate cancer cells. The vaccine combines the PSMA cancer antigen (recombinant soluble PSMA, or rsPSMA) with an immune stimulant to induce an immune response against prostate cancer cells. CYT-500 is designed to enable targeted delivery of a cytotoxic agent to PSMA-expressing cells, and is designed to enable targeted delivery of high doses of radiation to PSMA-expressing cells. PSMA is a protein abundantly expressed on the surface of prostate cancer cells, with an increased expression in high-grade cancers, metastatic disease and hormone-refractory prostate cancer.
Deal Structure: In June 1999, Progenix and Cytogen formed a joint venture (PSMA LLC) for the purposes of conducting research, development, manufacturing and marketing of products related to PSMA. By the terms of PSMA LLC, Cytogen is principally responsible for product marketing, and the companies share promotion rights. Each company owns 50% of PSMA LLC.
In February 2001, PSMA LLC entered into a worldwide exclusive licensing agreement with Abgenix to use Abgenixs XenoMouse technology for generating fully human antibodies to the joint ventures PSMA antigen. In return, PSMA LLC paid a license fee and is obligated to pay additional payments upon the occurrence of defined milestones associated with the development and commercialization program for products incorporating an antibody generated utilizing the XenoMouse technology. PSMA LLC is also required to pay royalties based upon net sales of any antibody products.
On April 24, 2006, Progenics Pharmaceuticals announced that it has acquired complete...See full deal structure in Biomedtracker
Partners: Jazz Pharmaceuticals plc Amgen, Inc.
Additional information available to subscribers only: